Skip to main content

Table 3 Changes in duration of morning stiffness, SF-36 PCS and MCS scores between baseline and 6 months by treatment group

From: Can hybrid hyaluronic acid represent a valid approach to treat rizoarthrosis? A retrospective comparative study

  Sinovial H-L Group (n = 55) Triamcinolone Group (n = 45) Difference in change scores between groups
T0 T4 Change T0 T4 Change  
Duration of morning stiffness (minutes)
 Mean ± SD 9.73 ± 11.78 3.98 ± 5.21 −5.75 ± 9.45 8.85 ± 4.13 8.2 ± 3.94 −0.65 ± 2.94 −5.10***
 Range 0–60 0–20 −40 − 5 0–15 0–15 -5-5  
SF-36 PCS
 Mean ± SD 35.93 ± 9.52 46.51 ± 7.28 10.57 ± 9.66 38.32 ± 8.71 39.94 ± 7.63 1.62 ± 3.12 8.95***
 Range 20.37–51.41 30.98–58.81 −11.45-25.07 20.43–54.03 22.88–54.1 −3.72-8.51  
SF-36 MCS
 Mean ± SD 50.41 ± 7.68 52.23 ± 9.11 1.81 ± 10.14 41.36 ± 9.52 41.7 ± 9.36 0.34 ± 2.48 1.47*
 Range 34.95–65.58 36.4–65.28 −15.84-19.55 17.21–56.32 16.13–56.09 −5.07-4.89  
  1. *p < 0.05; ***p < 0.001 Wilcoxon rank-sum test
  2. SF-36 PCS: Physical Components Summary, SF-36 MCS: Mental Component Summary; T0: time of the first injection; T4: month 6